Study of Rapamycin Plus Ketoconazole in Advanced Cancers

PHASE1CompletedINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

October 31, 2004

Primary Completion Date

December 31, 2008

Study Completion Date

December 31, 2008

Conditions
Advanced Cancer
Interventions
DRUG

Rapamycin

Oral Rapamycin once weekly at assigned dose in 4 week cycles. Dosing can continue until disease progression or severe side effects are seen.

DRUG

Ketoconazole

Twice daily (200mg each time) at the start of the second week of therapy for 4 consecutive days. Dosing continues every week after the second week of therapy.

Trial Locations (1)

60637

University of Chicago, Chicago

All Listed Sponsors
lead

University of Chicago

OTHER

NCT00708591 - Study of Rapamycin Plus Ketoconazole in Advanced Cancers | Biotech Hunter | Biotech Hunter